Clinical Trial Update: Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission. [Phase 2]

View source ↗

Summary

Phase 2 trial of PF-06687234 as add-on to infliximab in active ulcerative colitis (not in remission) was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• PF-06687234

Snippet

Sponsor: Pfizer | Conditions: Ulcerative Colitis | Phase 2 | Status: TERMINATED | Results posted: 2021-12-28